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Sir, We thank Dr Vishnu for his interest in our paper. We reported
atrophy of the caudate and thalamus in presymptomatic familial
Alzheimer’s disease mutation carriers at a stage when hippocampal
atrophy was not yet evident (Ryan et al., 2013). As Dr Vishnu
(2013) describes, brain atrophy on MRI is thought to be a bio-
marker of neuronal loss, which is considered to be a downstream
element in the amyloid cascade hypothesis of Alzheimer’s disease
pathogenesis. Dr Vishnu raises the question of whether the caud-
ate and thalamic atrophy we detected represents neuronal injury
induced by amyloid or by amyloid-independent mechanisms. We
agree that this is an important point and feel that it in fact high-
lights an even broader issue; that it is not yet clear what patho-
logical processes do account for the volume or other MRI-based
changes that may be witnessed in the presymptomatic phase of
Alzheimer’s disease. Although there are numerous clinicopatholo-
gical studies correlating atrophy on MRI with neuronal loss, Braak
neurofibrillary tangle stage and tau burden in patients with estab-
lished symptomatic Alzheimer’s disease (Zarow et al., 2005;
Whitwell et al., 2008), this information is lacking for the presymp-
tomatic stage. Various different processes may give rise to changes
in the volume of brain structures, some of which may be dynamic,
and this uncertainty should be taken into account in hypothetical
biomarker models of presymptomatic Alzheimer’s disease.
We proposed in our article (Ryan et al., 2013) that axonal injury
and subsequent degeneration may account for the thalamic and
caudate atrophy that we observed in the presymptomatic mutation
carriers. Support for this hypothesis came from the associated
changes in diffusivity indices that we found in both of these
subcortical grey matter structures and also in the cingulum.
Interestingly, the same pattern of diffusivity changes that we de-
tected in our presymptomatic mutation carriers has also been
observed in a diffusion tensor imaging study of the APPsw transgenic
mouse at the time of amyloid plaque accumulation (Sun et al., 2005).
The fact that this mouse model of Alzheimer’s disease does not de-
velop tau pathology perhaps indirectly supports the idea that neur-
onal injury in presymptomatic familial Alzheimer’s disease may be
induced by amyloid pathology alone.
Some support for the idea that processes other than overt neur-
onal loss may account for the thalamic atrophy evident on MRI
comes from one of the few autopsy studies to have specifically
examined the thalamus in patients with Alzheimer’s disease.
Xuereb et al. (1991) noted that, although there was significant
loss of thalamic volume in cases with Alzheimer’s disease, the
amount of neuronal loss was insufficient to account for degree
of atrophy. They hypothesized that the atrophy must instead be
due to loss of axons, dendrites and synaptic structures or to glial
cell changes. In our paper (Ryan et al., 2013), we focused on the
potential role that axonal degeneration may play in the develop-
ment of subcortical atrophy. However, it is also important to con-
sider the possibility that glial cell changes may contribute to the
volumetric MRI changes evident in presymptomatic familial
Alzheimer’s disease. Studies in a triple transgenic mouse model
of Alzheimer’s disease have revealed complex changes in astroglial
morphology during the early stages of the disease (Olabarria
et al., 2010). Before the appearance of neuritic amyloid plaques,
hippocampal astrocytes have been observed to undergo atrophy,
but once the plaques arise, those in close vicinity become gliotic
whilst those further away remain atrophied. One can envisage
that altering glial numbers or morphology might be reflected in
dynamic changes in the volume and diffusion characteristics of the
affected brain structures when studied with MRI at different time-
points in the presymptomatic stage.
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If immune-mediated mechanisms do play a role that is re-
flected in dynamic regional brain volume changes this could, as
Dr Vishnu notes, explain Fortea et al.’s (2010) contrasting find-
ings of caudate enlargement in presymptomatic familial
Alzheimer’s disease mutation carriers. However, drawing compari-
sons between different studies of presymptomatic familial
Alzheimer’s disease is difficult for a number of reasons. Not
only do they vary in how far from expected age at symptom
onset the subjects in the study are, they often use different
measures to define estimated age at onset. These include paren-
tal age at onset or the mean or median age at onset for the
family. It is not yet clear which of these predictors is most ac-
curate, nor how much natural variability in age at onset may be
expected within a family. The subjective nature of deciding what
constitutes the onset of ‘symptoms’ and variability in how this is
defined for the purpose of a study further complicates matters
(Ryan and Rossor, 2011). Finally, different techniques for seg-
menting a structure of interest like the caudate on MRI may
be employed by different studies and consistency between meth-
ods has not been systematically evaluated.
We agree with Dr Vishnu (2013) that studying mutation carriers
with a variety of biomarkers including amyloid imaging and CSF
measures of amyloid and tau, in addition to MRI, will be crucial to
understanding the mechanisms operating in presymptomatic
Alzheimer’s disease. Fortunately, initiatives like the Dominantly
Inherited Alzheimer Network and the Colombian Alzheimer’s
Prevention Initiative Registry are currently collecting such data in
large cohorts of presymptomatic individuals and cross-sectional
analyses have already provided insights into the probable se-
quence of biomarker changes (Bateman et al., 2012; Reiman
et al., 2012). Ultimately however, it is likely to be the longitudinal
analysis of multiple time-point multimodal data and ascertainment
of rates of change that will reveal the most information about the
underlying pathological mechanisms. Importantly, trials of disease-
modifying therapies for presymptomatic familial Alzheimer’s
disease will soon be launched and will include at least some as-
sessment of biomarker changes (Bateman et al., 2011). Biomarkers
have the potential to behave in unexpected ways following treat-
ment, as illustrated by the AN1792 amyloid-b active immunization
trial, in which it was the antibody-responders who showed the
greatest rates of atrophy (Fox et al., 2005). Given that immune
mechanisms may play a role in both the early disease process, and
in the strategies used to combat it with amyloid-immunomodula-
tory agents, efforts should be made to better understand how
such processes affect imaging biomarkers. A variety of imaging
techniques may play a role here including microglial activation
studies, as may the insights gained from imaging of animal
models. Much valuable work has been done to formulate hypo-
thetical models of Alzheimer’s disease biomarkers using evidence
gathered from studies of sporadic Alzheimer’s disease, mild cog-
nitive impairment and normal ageing (Jack et al., 2013). The
challenge now is to use longitudinal studies of presymptomatic
mutation carriers to better understand the temporal evolution of
biomarker changes during the natural history of familial
Alzheimer’s disease, so that these models may be further refined
and the optimal time for therapeutic intervention may be guided.
Funding
This work was supported by the Medical Research Council (Clinical
Research Training Fellowship G0900421 to NSR, Senior Clinical
Fellowship G116/143 to NCF). It was undertaken at UCLH/UCL,
who received a proportion of funding from the Department of
Health’s National Institute for Health Research (NIHR)
Biomedical Research Centres funding scheme, and was supported
by the NIHR Queen Square Dementia Biomedical Research Unit.
NCF is a NIHR senior investigator. The Dementia Research Centre
is an Alzheimer’s Research UK Co-ordinating Centre and has
received equipment funded by Alzheimer’s Research UK and
Brain Research Trust.
References
Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM,
et al. Autosomal-dominant Alzheimer’s disease: a review and pro-
posal for the prevention of Alzheimer’s disease. Alzheimers Res Ther
2011; 3: 1.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al.
Clinical and biomarker changes in dominantly inherited Alzheimer’s
disease. N Engl J Med 2012; 367: 795–804.
Fortea J, Sala-Llonch R, Bartre´s-Faz D, Bosch B, Llado´ A, Bargallo´ N,
et al. Increased cortical thickness and caudate volume precede atrophy
in PSEN1 mutation carriers. J Alzheimer’s Dis 2010; 22: 909–22.
Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al.
Effects of Abeta immunization (AN1792) on MRI measures of cerebral
volume in Alzheimer disease. Neurology 2005; 64: 1563–72.
Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS,
et al. Tracking pathophysiological processes in Alzheimer’s disease: an
updated hypothetical model of dynamic biomarkers. Lancet Neurol
2013; 12: 207–16.
Olabarria M, Noristani HN, Verkhratsky A, Rodrı´guez JJ. Concomitant
astroglial atrophy and astrogliosis in a triple transgenic animal model of
Alzheimer’s disease. Glia 2010; 58: 831–8.
Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-
Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young
adults at genetic risk for autosomal dominant Alzheimer’s disease in
the presenilin 1 E280A kindred: a case-control study. Lancet Neurol
2012; 11: 1048–56.
Ryan NS, Keihaninejad S, Shakespeare TJ, Lehmann M, Crutch SJ,
Malone IB, et al. Magnetic resonance imaging evidence for presymp-
tomatic change in thalamus and caudate in familial Alzheimer’s
disease. Brain 2013; 136 (Pt 5): 1399–414.
Ryan NS, Rossor MN. Defining and describing the pre-dementia stages
of familial Alzheimer’s disease. Alzheimer’s Res Ther 2011; 3: 29.
Sun SW, Song SK, Harms MP, Lin SJ, Holtzman DM, Merchant KM,
et al. Detection of age-dependent brain injury in a mouse model of
brain amyloidosis associated with Alzheimer’s disease using magnetic
resonance diffusion tensor imaging. Exp Neurol 2005; 191: 77–85.
Vishnu VY. Implications of presymptomatic change in thalamus and cau-
date in Alzheimer’s disease. Brain 2013; doi:10.1093/brain/awt167.
Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA,
Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology
at autopsy: a voxel-based morphometry study. Neurology 2008; 71:
743–9.
Xuereb JH, Perry RH, Candy JM, Perry EK, Marshall E, Bonham JR. Nerve
cell loss in the thalamus in Alzheimer’s disease and Parkinson’s disease.
Brain 1991; 114 (Pt 3): 1363–79.
Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al.
Correlates of hippocampal neuron number in Alzheimer’s disease and
ischemic vascular dementia. Ann Neurol 2005; 57: 896–903.
e259 | Brain 2013: 136; 1–2 Letter to the Editor
